SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of ...
MYQORZO was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms, and by the China National Medical ...
The study tests mavacamten, an oral heart drug designed to improve how the heart muscle relaxes and pumps in hypertrophic cardiomyopathy. The treatment aims to cut symptoms like shortness of breath ...
Edgewise Therapeutics (NASDAQ:EWTX) highlighted multiple upcoming milestones across its cardiac and neuromuscular programs during a presentation at Guggenheim’s 2026 Healthcare Innovations Conference.
ACACIA-HCM is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of aficamten compared to placebo on health-related quality of life in ...
BOSTON--(BUSINESS WIRE)--Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart ...
SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and ...
Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results